Perennial Investment Advisors LLC Purchases New Stake in Thermo Fisher Scientific Inc. $TMO

Perennial Investment Advisors LLC acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,720 shares of the medical research company’s stock, valued at approximately $863,000.

A number of other hedge funds also recently modified their holdings of the stock. Legacy Wealth Managment LLC ID raised its stake in shares of Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after buying an additional 22 shares during the period. Kilter Group LLC purchased a new position in shares of Thermo Fisher Scientific in the second quarter worth about $25,000. Allied Private Wealth LLC purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at approximately $26,000. High Note Wealth LLC boosted its holdings in Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after buying an additional 29 shares during the period. Finally, Swiss RE Ltd. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $28,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Up 1.0%

Shares of TMO stock opened at $634.48 on Thursday. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The firm has a market cap of $234.60 billion, a P/E ratio of 34.13, a price-to-earnings-growth ratio of 2.56 and a beta of 0.85. The business has a 50-day moving average price of $552.22 and a two-hundred day moving average price of $510.70. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $647.00.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. During the same period last year, the business earned $4.28 earnings per share. The business’s quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.11%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 275 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $627.05, for a total value of $172,438.75. Following the transaction, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $77,707,171.25. The trade was a 0.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the transaction, the chief accounting officer owned 2,966 shares in the company, valued at $1,734,546.46. This represents a 12.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 73,768 shares of company stock valued at $44,122,820. 0.33% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of recent analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and set a $630.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Evercore set a $570.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. Wells Fargo & Company dropped their price objective on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Finally, Morgan Stanley raised their price target on Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $619.41.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.